New device targets recurrent brain tumors in early trial
NCT ID NCT05303467
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 31 times
Summary
This early study tests a device called TheraSphere GBM in 36 people whose glioblastoma has come back after prior treatment. The device delivers tiny radioactive beads directly to the tumor to try to control it. The main goal is to check if the procedure is safe, not yet whether it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Interventional Radiology Center
WITHDRAWNBaltimore, Maryland, 21287, United States
-
Lenox Hill Hospital
RECRUITINGNew York, New York, 10075, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Jacksonville
RECRUITINGJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwestern Univerity
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Alabama Birmingham
WITHDRAWNBirmingham, Alabama, 35294, United States
-
University of California San Diego
NOT_YET_RECRUITINGSan Diego, California, 92103, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63130, United States
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TheraSphere GBM (Y-90 glass microspheres delivered via device)
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, potentially slowing tumor growth.
What could go wrong
This is a very early Phase 1 safety study with only 36 participants. It is not designed to prove effectiveness, and there are risks of serious side effects like brain radiation necrosis or blood-related toxicities.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.